All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional.
An expert panel hosted by
Customizing first-line BTK inhibitors for CLL
with Gilles Salles, Paolo Ghia, and Francesc Bosch
Wednesday, October 23, 2024
18:30-19:30 BST
This independent educational activity is supported by Pharmacyclics LLC, an AbbVie Company and Janssen Biotech. All content is developed independently by the faculty. The funder is allowed no influence on the content of this activity.
The Lupus Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lupus Hub cannot guarantee the accuracy of translated content. The Lupus Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Lupus Hub is an independent medical education platform, supported through a grant from AstraZeneca. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Patients with systemic lupus erythematosus (SLE) experience susceptibility to thrombotic events due to chronic inflammation, vascular damage, and acquired coagulation disorders resulting from antiphospholipid antibodies (aPL).
Nossent et al. recently published an article in Lupus, comparing the incidence rates (IRs), risk factors, and outcomes of a first venous thromboembolic event (VTE) between patients with SLE and controls. Here, we summarize their key findings.
Figure 1. Incidence rates per 1,000 person-years for VTE, PE, and VT in patients with SLE vs controls*
PE, pulmonary embolism; VT, venous thrombosis; VTE, venous thromboembolic event, SLE, systemic lupus erythematosus
*Data from Nossent , et al.1
Figure 2. Adjusted hazard ratio for association between A risk factors and a first VTE and B death and arterial events following first VTE in patients with SLE vs controls*
aHR, adjusted hazard ratio; CI, confidence interval; SLE, systemic lupus erythematosus.
*Data from Nossent, et al.1
Key learnings |
|
Subscribe to get the best content related to lupus delivered to your inbox